cancerclass: An R Package for Development and Validation of Diagnostic Tests from High-Dimensional Molecular Data
暂无分享,去创建一个
Budczies Jan | Daniel Kosztyla | Christian von Törne | Albrecht Stenzinger | Silvia Darb-Esfahani | Manfred Dietel | Carsten Denkert | A. Stenzinger | C. Denkert | M. Dietel | S. Darb-Esfahani | Daniel Kosztyla | C. Toerne | Budczies Jan
[1] J. Budczies,et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. , 2009, Gastroenterology.
[2] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[3] R. Tibshirani,et al. Outlier sums for differential gene expression analysis. , 2007, Biostatistics.
[4] Royston Goodacre,et al. Metabolic fingerprinting as a diagnostic tool. , 2007, Pharmacogenomics.
[5] Anders Larsson,et al. Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer , 2009, Upsala Journal of Medical Sciences.
[6] C. Sotiriou,et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Sparano,et al. TAILORx: trial assigning individualized options for treatment (Rx). , 2006, Clinical breast cancer.
[8] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[9] F. Kittrell,et al. Overexpression of Separase induces aneuploidy and mammary tumorigenesis , 2008, Proceedings of the National Academy of Sciences.
[10] Cor J. Veenman,et al. A protocol for building and evaluating predictors of disease state based on microarray data , 2005, Bioinform..
[11] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[12] Kevin C. Dorff,et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models , 2010, Nature Biotechnology.
[13] Edward R. Dougherty,et al. Is cross-validation valid for small-sample microarray classification? , 2004, Bioinform..
[14] Xia Yun,et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings , 2010, International Journal of Clinical Oncology.
[15] J. Stec,et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Leming Shi,et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors , 2010, Breast Cancer Research.
[17] H. Katabuchi,et al. Thymidine kinase in epithelial ovarian cancer: Relationship with the other pyrimidine pathway enzymes , 2002, International journal of cancer.
[18] Edward R. Dougherty,et al. Is cross-validation better than resubstitution for ranking genes? , 2004, Bioinform..
[19] Stefan Michiels,et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.
[20] Geoffrey J McLachlan,et al. Selection bias in gene extraction on the basis of microarray gene-expression data , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] R. Tibshirani,et al. Improvements on Cross-Validation: The 632+ Bootstrap Method , 1997 .
[22] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[23] W. Weichert,et al. A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.
[24] R. Spang,et al. Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] Yusuke Nakamura,et al. Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells , 2007, Cancer science.
[26] R. Greil,et al. A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.
[27] M. Stratton,et al. The cancer genome , 2009, Nature.
[28] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[30] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[31] Jeremy J. W. Chen,et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.
[32] Philip Lijnzaad,et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas , 2005, Nature Genetics.
[33] Rainer Spang,et al. Computational diagnostics with gene expression profiles. , 2008, Methods in molecular biology.
[34] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[35] Hanlee P. Ji,et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. , 2006, Nature biotechnology.
[36] Baolin Wu,et al. Cancer outlier differential gene expression detection. , 2007, Biostatistics.
[37] S. Dudoit,et al. Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .
[38] H. Höfler,et al. Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay , 2012, Virchows Archiv.
[39] David Cameron,et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.
[40] J. Becker,et al. The Universal Character of the Tumor-Associated Antigen Survivin , 2007, Clinical Cancer Research.
[41] Fatima Cardoso,et al. The MINDACT trial: The first prospective clinical validation of a genomic tool , 2007, Molecular oncology.